Is BIIB above its 150-day moving average?

BIIB is currently above its 150-day moving average by 9.37%. The MA150 sits at $179.56.

What is BIIB's RSI right now?

BIIB's 14-period RSI is 57.0. This is in a neutral zone (30–70).

Is BIIB's MACD bullish or bearish?

BIIB's MACD histogram reads -0.0444. A negative histogram means short-term momentum is leaning bearish.

How are BIIB's technical signals calculated?

Scanance computes BIIB's technicals daily after market close from end-of-day OHLCV data. MA150 and MA200 are simple moving averages. RSI uses Wilder's 14-period smoothing. MACD uses 12/26/9 exponential moving averages. Volume ratio compares current volume to the 20-day average.

Scanance does not provide investment advice. The technical readouts on this page are pattern matches against deterministic indicator rules — they are not buy or sell recommendations. Always do your own research and consider consulting a licensed financial professional before making any trade.

BI

Biogen Inc.

BIIBHealthcareNASDAQ

Drug Manufacturers - General

PriceMA150MA200

Loading chart…

End-of-day data · ScananceOpen live chart on TradingView ↗

Indicator snapshot

MA150+9.37%

$179.56

Price above medium-term moving average.

MA200+15.38%

$170.22

Above long-term trend line.

RSI-14neutral

57.0

Balanced. Not overbought, not oversold.

MACDnegative

-0.0444

Histogram negative — downward momentum.

Financials · Annual

Revenue

$9.89B

+2.2% YoY

Net Income

$1.29B

-20.8% YoY

EBITDA

$2.60B

-8.0% YoY

Free Cash Flow

$1.92B

Scan Results

Daily timeframe

DateIndicatorDetails

About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. At a $28.99B market cap, Biogen Inc. ranks as a large-cap company within healthcare. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.

Key stats

Market Cap$28.99B

P/E (TTM)21.09

Fwd P/E11.84

EPS$9.31

Beta0.20

52W Change+51.3%

ROE7.7%

Analysis

The company holds $4.28B in cash, though total debt stands at $6.56B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $1.92B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 7.7% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $10.17B (2022) to $9.89B (2025).

BIIB's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BIIB.

Links

Company website ↗

Biogen Inc.

News & analytics is part of Premium.

Technical readouts are part of Premium.